

MEETING MINUTES

Consortium for Medical Marijuana Clinical Outcomes Research: BOARD MEETING

Monday, June 16th, 2025, at 10:00 am (EDT)

Remote Connection via Zoom

Board Members Present (none absent):

Max C. E. Orezzaoli
Martha S. Rosenthal
Christopher R. McCurdy
Eric H. Holmes
Jacqueline Sagen
William Anderson
Dinender K. Singla
Charles A. Weatherford
Peter Holland
Troy Quast
Ken Dawson-Scully

Team Members Present:

Almut G. Winterstein
Robert L. Cook
Jeevan Jyot
Allison Veliz

Opening Remarks

Dr. Max Orezzaoli, chair of the Consortium board, called the meeting to order at 10:03 AM EDT and welcomed all board members.

Consortium Funding Update

Dr. Almut Winterstein, director of the Consortium, welcomed everyone and informed the board that the Consortium has not yet received confirmation that the annual \$1.5 million of funding has been approved. Dr. Almut Winterstein handed the meeting over to Dr. Jeevan Jyot to discuss the Grants program summary and scoring method.

Discussion of Grant Proposals Scoring Method

The Consortium received 38 Letters of Intent (LOIs) and after review and board approval, 35 full proposals were invited and 33 full proposals received. Those proposals were reviewed by out of state ad-hoc reviewers with demonstrated expertise in the respective research area, using NIH scoring guidelines.

Drs. Winterstein and Jyot provided an overview of the scoring method. No board members or Consortium faculty in attendance had conflicts of interests with any proposal reviewed. The Board began discussion on funding the renewal of the two level 2 awards from the 2024 grants cycle. Based on the evaluation of the year 1 progress reports, the board agreed to grant second year funding for both of the proposals. Dr. Orezzaoli recommended the board triage proposals submitted in this cycle that had an overall impact score of 3.5 or higher. All members agreed and the remaining 12 proposals were discussed in order, starting from those with the best overall impact scores.

Review of Grant Proposals Based on Reviewer Scores

Based upon the suggested approach, the individual proposal together with the reviewer comments were discussed in detail. Dr. Jyot briefly described each proposal to the board, highlighted strengths and weaknesses reported by reviewers and initiated discussion. The board members also assessed each proposal's relevance to the Consortium's research mission, immediate clinical and/or demonstrable translational relevance to inform medical use of marijuana and outcomes of its use, as well as responsiveness to the Consortium research priorities. Based upon the available funding, the board agreed to fund five proposals for the one-year level, and one additional proposal for the two-year level funding mechanism.

Vote on Grants Program Proposals

Dr. Orezza asked for a vote from board members regarding each individual proposal. All board members present voted in favor of funding the six proposals and continuing the second-year funding for the two 2024 Level 2 proposals. No board member opposed the decision, and no board members abstained from voting.

Discussion of CCORC Timing

Dr. Winterstein opened up a discussion of moving the timing of the Consortium's annual conference, the Cannabis Clinical Outcomes Research Conference, from May 2026 to November 2026. This could possibly bring in more attendance from those traveling from the north, who may want to enjoy Florida's winter weather. Early November would be ideal, as it would be after the hurricane season and before the Thanksgiving holiday. Another item Dr. Winterstein shared was a conversation with researchers in Colorado interested in exploring a potential collaboration with the Cannabis Research Conference. This could potentially attract increased interest, and boost CCORC's outreach. This may result in the need for a larger venue raising associated costs.

The board consensus was in favor of moving the conference to the winter, as long as the dates did not coincide with other large conferences. A poll would be sent out to board members and grant awardees to gauge availability on specific dates. As regards collaborating with another conference, the board recommended the idea be explored further and brought back once more details have been expanded upon.

Public Comments

The Chair invited comments from the public and none were submitted.

Closing Remarks

Dr. Orezza and Dr. Winterstein closed the meeting by thanking the board members.

Adjournment

Dr. Orezza adjourned the meeting at 11:54 AM.